NGM Biopharmaceuticals

CA - South SFPharmaceutical1 H-1B visas (FY2023)

Focus: NGM Biopharmaceuticals is a clinical-stage biotech focused on metabolic diseases and neurology, with a pipeline spanning diabetes, liver disease, obesity, oncology, and ophthalmology. The company is based in South San Francisco and operates as a mid-cap biotech with no marketed products.

Metabolic Diseases Neurology

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Open Jobs

About NGM Biopharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow NGM Biopharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

26 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Aldafermin

Impaired Hepatic Function

Phase 1

Clinical Trials (1)

NCT04823702Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Phase 1

Help build intelligence for NGM Biopharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline with 26 programs across 12 Phase 1, 14 Phase 2, and 1 Phase 3 program, offering exposure to multiple therapeutic modalities and disease areas
Strong focus on high-value indications including obesity (NGM313, NGM395), liver disease (NGM282, Aldafermin), and oncology (NGM120, NGM831), aligned with current pharma innovation priorities
Located in South San Francisco biotech hub with access to talent, CRO partnerships, and investor ecosystem

Watch Out For

Zero active job openings at the time of this analysis suggests potential hiring freeze or transition phase, limiting near-term career entry points
No marketed products and pre-revenue status means financial stability depends entirely on continued funding and clinical trial success; cash burn profile unknown
Pipeline is early-stage heavy (12 Phase 1 programs vs. only 1 Phase 3), indicating 5-7+ years minimum before first potential commercialization; long path to value realization

Generated by Claude from NGM Biopharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NGM621

Geographic Atrophy

Phase 1

Clinical Trials (1)

NCT04014777Study of NGM621 in Participants With Geographic Atrophy

Phase 1

NGM831

Pancreatic Cancer

Phase 1

NGM438

Pancreatic Cancer

Phase 1

Aldafermin

Healthy Male

Phase 1

Clinical Trials (1)

NCT04828265Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Phase 1

NGM282

Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01776528Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

Phase 1

NGM395

Obesity

Phase 1

Clinical Trials (1)

NCT04187339Study of NGM395 in Adult Participants

Phase 1

Aldafermin

Impaired Renal Function

Phase 1

Clinical Trials (1)

NCT04179630Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Phase 1

NGM313

Obesity

Phase 1

Clinical Trials (1)

NCT02708576Phase 1 Study of NGM313 in Healthy Adult Participants

Phase 1

NGM120

Cachexia

Phase 1

Clinical Trials (1)

NCT03392116Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Phase 1

NGM313

Obese

Phase 1

Clinical Trials (1)

NCT03298464Study of NGM313 in Obese Participants

Phase 1

NGM707

Mesothelioma

Phase 1/2

Clinical Trials (1)

NCT07511972Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 2

NGM282

Functional Constipation

Phase 1/2

Clinical Trials (1)

NCT02649062Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

Phase 1/2

NGM621

SARS-CoV-2 Infection

Phase 1/2

Clinical Trials (1)

NCT04582318A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

Phase 1/2

NGM120 30mg

Pancreatic Cancer

Phase 1/2

Clinical Trials (1)

NCT04068896Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Phase 1/2

NGM282

Primary Biliary Cirrhosis

Phase 2

Clinical Trials (1)

NCT02135536Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Phase 2

NGM120 Q4W

Colorectal Cancer

Phase 2

Clinical Trials (1)

NCT07033026An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Phase 2

aldafermin

Compensated Cirrhosis

Phase 2

Clinical Trials (1)

NCT04210245Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Phase 2

NGM282

Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT01943045Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

Phase 2

Aldafermin

Chronic Diarrhea

Phase 2

Clinical Trials (1)

NCT05130047Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Phase 2

NGM621

Geographic Atrophy

Phase 2

Clinical Trials (1)

NCT04465955A Study of NGM621 in Participants With Geographic Atrophy

Phase 2

NGM282

Primary Biliary Cirrhosis

Phase 2

Clinical Trials (1)

NCT02026401Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Phase 2

NGM282

NASH - Nonalcoholic Steatohepatitis

Phase 2

Clinical Trials (1)

NCT03912532Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

Phase 2

NGM282

Primary Sclerosing Cholangitis

Phase 2

Clinical Trials (1)

NCT02704364A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Phase 2

NGM282

Nonalcoholic Steatohepatitis (NASH)

Phase 2

Clinical Trials (1)

NCT02443116Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Phase 2

aldafermin

Primary Sclerosing Cholangitis

Phase 2/3

Clinical Trials (1)

NCT06654726A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 24 clinical trials

Top TAs: Gastroenterology, Metabolic Diseases, Infectious Diseases

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

5 pipeline

4 pipeline

3 pipeline

2 pipeline

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2025-04-29

85 employees affected— CA

source

Source: state DOL filings, aggregated via Big Local News

No major regulatory or operational red flags detected; pre-revenue status remains the primary structural risk.